The aim of this study was to assess the feasibility of targeted radionuclide therapy of thyroid carcinoma, first exploring potential targets BRAF, EGFR and CD44v6 in patient material through immunohistochemistry (IHC) and pyrosequencing. This evidence concerns the gene EGFR and thyroid gland carcinoma.